Guggenheim Securities has reduced its price target for Zevra Therapeutics to $24 per share, citing a recent European regulatory setback for the biopharmaceutical company's lead drug candidate. The move underscores the challenges facing Zevra as it seeks to expand its market beyond the United States.
The US-based analyst downgrade comes after European authorities raised concerns over the drug's clinical data package, delaying approval prospects in the EU. Zevra had been pursuing European approval to broaden revenue streams, but the setback has forced Guggenheim to reassess the stock's valuation and near-term growth trajectory.
Zevra Therapeutics, which focuses on rare disease treatments, already holds US marketing authorisation for the therapy in question. However, the European market represents a significant commercial opportunity, and the regulatory hurdle has dampened investor sentiment. Shares of Zevra have moved lower in recent trading sessions, reflecting the market's disappointment.
For UK investors and pension funds with exposure to US-listed biotech stocks through global equity funds or ETFs, the downgrade serves as a reminder of the regulatory risks inherent in the sector. European approval processes can diverge sharply from the US Food and Drug Administration's decisions, creating volatility for companies reliant on international expansion.
Analysts note that while Zevra's US business remains intact, the European setback may delay profitability targets and increase cash burn as the company potentially pursues additional clinical trials. Guggenheim's revised target implies a modest upside from current levels, but the stock remains under pressure as the market digests the news.